BAG-1、p53表达与NSCLC新辅助化疗疗效分析Expression of BAG-1 and p53 in relation to efficacy of neo-adjuvant chemotherapy in patients with NSCLC
曾辉,龚晓成,韩建伟,许朝阳
摘要(Abstract)：
目的探讨Ⅲ期非小细胞肺癌(NSCLC)患者BAG-1、p53蛋白表达与新辅助化疗疗效之间的关系。方法通过免疫组织化学法检测57例Ⅲ期NSCLC患者BAG-1、p53蛋白表达水平,并研究上述指标的表达与新辅助化疗疗效之间的关系。结果 BAG-1的表达与NSCLC的分化程度有关(P<0.05),BAG-1与p53蛋白的表达无相关性(r=-0.136,P>0.05)。BAG-1表达与新辅助化疗疗效无相关性(P>0.05),p53表达与新辅助化疗疗效无相关性(P>0.05),BAG-1与p53共同表达与新辅助化疗疗效无相关性(P>0.05)。结论化疗前Ⅲ期NSCLC患者BAG-1与p53均表达阳性者较阴性者新辅助化疗有效率低,但差异无统计学意义。
关键词(KeyWords)： 癌,非小细胞肺/药物疗法;化学疗法,辅助;载体蛋白质类;基因,p53;基因表达;治疗结果;免疫组织化学
基金项目(Foundation):
作者(Author): 曾辉,龚晓成,韩建伟,许朝阳
DOI: 10.13267/j.cnki.syzlzz.2014.02.019
参考文献(References)：
- [1]Rosell R,Gomez-Codina J,Camps C.Preresectional chemotherapy in stageⅢA non-small-cell lung cancer:a7-year assessment of a randomized controlled trial[J].Lung Cancer,1999,26(1):7-14.
- [2]Greene FL,Page DL,Fleming ID,et al.AJCC cancer staging manual[M].6th ed.NewYork:Springer,2002:225-228.
- [3]Travis WD,Colby TV,Corrin B,et al.Histological typing of lung and pleural tumours[M]//WHO:World Health Organization international histological classification of tumours.3rd ed.New York:Springer,1999:551-562.
- [4]陈翔,李坚,王洪林.Bag-1及p53基因在胆管癌组织中表达的研究[J].中国现代医学杂志,2006,16(12):1789-1791.
- [5]Ferguson MK.Optimal management when unsuspected N2nodal disease is identified during thoracotomy for lung cancer:cost-effectiveness analysis[J].J Thorac Cardiovasc Surg,2003,126(6):1935-1942.
- [6]Lin Y,Wang Z,Liu L,et al.Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stresstolerant human lung cancer cells[J].Lung Cancer,2011,71(3):291-297.
- [7]Sjostrom J,Blomqvist C,von Boguslawski K,et al.The predictive value of bcl-2,bax,bcl-xL,bag-1,fas,and fasL for chemotherapy response in advanced breast cancer[J].Clin Cancer Res,2002,8(3):811-816.
- [8]王巍,林耀东,陈泽程,等.定量检测血清p53抗体预测晚期非小细胞肺癌预后[J].实用肿瘤杂志,2011,26(1):46-49.
- [9]汪进良,焦顺昌,叶平,等.非小细胞肺癌患者p53蛋白异常表达与铂类化疗敏感性的Meta分析[J].南方医科大学学报,2008,28(5):770-773.
- [10]Odriscoll L,Linehan R,M Kennedy S,et al.Lack of prognostic significance of survivin,survivin-deltaEx3,survivin-2B,galectin-3,bag-1,bax-alpha and MRP-1mRNAs in breast cancer[J].Cancer Lett,2003,201(2):225-236.